

# CITATION REPORT

List of articles citing

## Antibody-Drug Conjugates in Urothelial Carcinomas

DOI: 10.1007/s11912-020-0879-y  
Current Oncology Reports, 2020, 22, 13.

**Source:** <https://exaly.com/paper-pdf/84228724/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
18	Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes. <i>Marine Drugs</i> , <b>2020</b> , 18,	6	28
17	Bladder Cancer: A Review. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 1980-1991	27.4	195
16	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	38
15	High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
14	Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 863-873	5.4	1
13	Advances in the management of urothelial carcinoma: is immunotherapy the answer?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 1743-1759	4	1
12	Role of Nectin-4 protein in cancer (Review). <i>International Journal of Oncology</i> , <b>2021</b> , 59,	4.4	1
11	Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma. <i>Future Oncology</i> , <b>2022</b> , 18, 21-33	3.6	2
10	The Cost of Enfortumab Vedotin Wastage Due to Vial Size-A Real-World Analysis. <i>Cancers</i> , <b>2021</b> , 13,	6.6	0
9	Antibody-Drug Conjugate Targets, Drugs and Linkers.. <i>Current Cancer Drug Targets</i> , <b>2022</b> ,	2.8	0
8	Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer.. <i>Frontiers in Molecular Biosciences</i> , <b>2021</b> , 8, 800945	5.6	0
7	Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 858865	5.3	0
6	Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer. <i>Journal of Nanobiotechnology</i> , <b>2022</b> , 20,	9.4	0
5	Is antibody-drug conjugate a rising star for clinical treatment of solid tumors? A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2022</b> , 177, 103758	7	0
4	Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K/AKT/NF- $\kappa$ B signaling by down-regulation of miR-520c-3p. <b>2022</b> , 22,		0
3	The era of personalized treatments: Updates on immunotherapy within urothelial of bladder cancer. <b>2022</b> , 16, 117-120		0
2	Precision Medicine in the Treatment of Locally Advanced or Metastatic Urothelial Cancer: New Molecular Targets and Pharmacological Therapies. <b>2022</b> , 14, 5167		0

1 Bone Metastasis in Bladder Cancer. **2023**, 13, 54

o